11.50 USD
▲+0.08+0.74%
盘后 11.31 0.00%
2026-09-16
市值
$59.14M
市盈率
—
EPS
-2.40
股息率
—
52 周区间
8.48 – 16.98
成交量
3.39K
Beta
0.49
目标价
39.00
52W 低 8.4852W 高 16.98
价格走势
公司简介
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients wit...